Pfizer arthritis drug succeeds in late stage trial | Reuters

Tasocitinib is a  JAK-STAT inhibitor, affecting the signaling of proteins involved in inflammatory and autoimmunity

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)